TABLE 1

Clinical characteristics and pulmonary function in patients admitted between January 1, 2004 and December 31, 2017

Clinical characteristics
COPD diagnosis23/43 (54.8%)
Respiratory failure18/43 (41.9%)
Asthma8/43 (18.6%)
Bronchiectasis13/43 (30.2%)
Interstitial lung disease2/43 (4.7%)
Silicosis1/43 (2.3%)
OSA16/43 (37.2%)
Emphysema17/43 (39.5%)
Chronic heart disease18/43 (41.9%)
Arterial hypertension19/43 (44.2%)
Diabetes7/43 (16.3%)
Neoplasia14/43 (32.6%)
Chronic hepatitis B1/43 (2.3%)
Chronic hepatitis C4/43 (9.3%)
Lung surgery
 Therapeutic pneumothorax6/43 (14.0%)
 Other lung surgical procedures3/43 (7.0%)
Patients with airflow obstruction (n=29)Nonsmokers (n=6)Smokers (n=23)p-value
Respiratory function
 FEV1 L0.8 (0.8–0.9)1.1 (0.9–1.6)0.03
 FEV1 %46.0±11.148.3±17.20.73
 FVC L1.7±0.82.7±0.90.004
 FVC %69.2±15.178.5±18.60.20
 FEV1/FVC52.1±12.745.5±12.70.21
 RV %165.6±37.0142.7±37.70.17
DLCO %60.8±22.4
6MWT
 Distance covered m364.1±144.1375.1±121.50.83
 Distance % predicted81.7±31.481.5±24.40.99
SpO2 baseline94.0±1.194.2±1.60.74
SpO2 average90.6±3.989.3±3.80.40
SpO2 min87.8±5.586.3±5.10.47
Pulmonary functionPatients with impaired respiratory pattern# (n=34)Patients with normal respiratory pattern (n=9)
Pre-pulmonary rehabilitationPost-pulmonary rehabilitationp-valuePre-pulmonary rehabilitationPost-pulmonary rehabilitationp-value
Lung function tests
 FEV1 L1 (0.8–1.3)1.1 (0.9–1.4)<0.00012.3 (1.9–2.6)2.5 (1.9–2.9)0.21
 FEV1 %48.3 (38.3–59.6)53.4 (44.0–65.0)<0.000185.2 (81.0–95.4)98.1 (85.7–105.6)0.21
 FVC L2.3±0.92.4±0.90.092.5±0.72.8±0.80.08
 FVC %73.7±17.778.8±16.90.00394.6±16.789.5±37.30.70
 FEV1/FVC51.4±15.152.4±14.80.2377.6±6.281.1±13.80.41
 RV %137.1 (111.9–178.9)147 (106.3–173.6)0.24113.9 (92.7–132.6)106.9 (100.8–124.8)1.0
DLCO %60.1±20.5
BGA
PaO266.2±7.370.9±7.20.00966.3±5.484.9±0.80.12
PaCO241.6±6.439.9±6.00.1039.6±1.034.6±2.80.16
 PH7.4±0.07.4±0.00.807.5±0.07.4±0.00.03
SaO294.3 (92.8–95.5)95.1 (93.1–96.2)0.0195.5 (94.1–96.2)96.8 (96.7–96.8)0.18
FIO221 (21–21)21 (21–21)0.32
6MWT
 Distance covered m371±127.5406±133.50.01407±82.2466±62.50.05
 Distance % predicted82.1±27.589.7±28.30.0186.0±20.398.4±19.20.05
 HR baseline80.3±9.981.9±13.60.4375.0±10.278.9±9.10.40
 HR average102.1±12.6105.9±13.00.03100.4±7.4100.5±10.20.97
 HR max112.9±14.5116.7±14.50.08111.5±11.9111.6±15.10.98
SpO2 baseline94.3±1.794.8±1.70.1095.8±0.995.9±1.00.81
SpO2 average90 (87–94)91.5 (88.5–94.5)0.0595 (94–96)96 (94.5–96.0)1.0
SpO2 min88 (83–91)89 (86.0–92.5)0.0594 (93–95)94 (92–95)0.89
 Modified Borg dyspnoea baseline0 (0–2)0 (0–1)0.790 (0–1)0 (0–2)0.68
 Modified Borg dyspnoea final4 (2–5)3 (0.5–4.0)0.0064 (1–5)2.5 (1.5–4.5)0.14
 Modified Borg fatigue baseline0 (0–1)0 (0.0–0.8)0.770.5 (0–2)0.8 (0.0–1.5)0.94
 Modified Borg fatigue final3 (2–5)2.5 (0–4)0.0091 (0–7)4 (0.5–4.5)0.77
Spontaneous walking SpO2
 Initial FIO221 (21–32)26 (21–30)0.40
SpO2 baseline93.2±1.395.2±1.30.10
SpO2 average89.5 (88.7–91.5)91.5 (90.7–93.2)0.04
SpO2 min86 (84–89)89 (87–90)0.03

Data are presented as mean±sd or median (interquartile range), unless otherwise stated, COPD: chronic obstructive pulmonary disease; OSA: obstructive sleep apnoea; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; RV: residual volume; DLCO: diffusing capacity of the lung for carbon monoxide; 6MWT: 6-min walk test; SpO2: peripheral capillary oxygen saturation; BGA: blood gas analysis; PaO2: partial pressure of arterial oxygen; PaCO2: partial pressure of arterial carbon dioxide; PH: potential of hydrogen; SaO2: oxygen saturation in arterial blood; FIO2: fraction of inspired oxygen: HR: heart rate. #: patients with obstructive or restrictive or mixed pattern.